Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that BTP levels in cerebrospinal fluid might help diagnose CIDP and predict therapy response but require validation in larger cohorts.

This study demonstrated that derivatives of dehydroepiandrosterone (2a-b, 3a-f, and 4a-f) significantly reduced viable LNCaP prostate cancer cells, suggesting potential therapeutic use for metastatic prostate cancer, while finasteride did not alter cell viability.

In this review, BTXA treatment was reported to effectively increase hair density and improve follicle health in androgenetic alopecia patients by enhancing scalp blood flow and reducing inflammation, without significant adverse effects.

This research developed a pig graph pangenome assembly of 27 genomes, revealing the importance of structural variations in adaptation and breed-specific traits, with BTF3 identified as a key gene influencing intramuscular fat and meat quality.

In this study, researchers used a UV-Vis Spectrophotometer to qualitatively and quantitatively analyze Dutasteride residues in human plasma, achieving a total recovery rate of 64.992%, and determined that the BTB reagent effectively selected compounds not analyzed in their research.

This opinion article reviews various pathways through which onabotulinumtoxinA might work in medical treatments, highlighting applications beyond muscle paralysis, including pain inhibition and potential effects on hair loss and cancer cell apoptosis.

This study reviews current trends and the state of research on botulinum toxin in dermatology, aiming to help researchers identify key areas and explore new research directions.

This study found that botulinum toxin type A inhibited apoptosis in dermal papillary cells induced by dihydrotestosterone through the circ_0135062/miR-506-3p/Bax axis.

This study found that botulinum toxin type A may reduce apoptosis in dermal papillary cells induced by dihydrotestosterone through the circ_0135062/miR-506-3p/Bax axis.

In this case study, Botulinum toxin type A injections were associated with improved hair growth and scalp condition in a patient with radiation-induced alopecia, though the mechanisms remain speculative.

This study found that endophytic bacteria isolated from Leea indica leaves showed high antioxidant activity, suggesting they could be a novel source of natural antioxidants.

This study found that botulinum toxin type A injections in stressed mice appeared to normalize hair follicle regeneration cycles and reduced stress-related hair loss indicators.

Botulinum toxin may help treat male pattern baldness.

This review discusses biotin and biotinidase deficiencies, their symptoms, and methods of medical management, without presenting new clinical findings.

This review discusses the biological properties and potential applications of PCL and barium titanate composites in biomedical fields and reports no new experimental findings; the authors highlight the need for further research.

In this study on rats, botulinum toxin–A injection was reported to reduce contraction in wounds and skin grafts, with changes in inflammation and collagen arrangement also observed.

This study found that botulinum toxin type A significantly reduced skin flap necrosis in rats exposed to cigarette smoke, suggesting it may help improve flap viability in smokers.

In this study of Danioninae species, researchers reported that the presence of breeding tubercles on the pectoral fins is conserved in certain species and linked to local androgen conversion, with steroid 5-α-reductase playing a crucial role in their development.

This paper highlights the emerging trend of treating androgenic alopecia with botulinum toxin, despite insufficient scientific evidence supporting its effectiveness.

In this study, botulinum toxin type A did not improve clinical features in patients with recalcitrant alopecia totalis or alopecia universalis over a four-month period.

This review examines current literature on botulinum toxin type A for androgenetic alopecia, reporting an association with increased hair growth and improved hair density, though further research is needed.

This study found that both intradermal botulinum toxin A and intradermal minoxidil were equally effective for treating androgenetic alopecia, showing improvement in hair count with advantages like minimal invasiveness and absence of major side effects; minoxidil was also noted to be more cost-effective.

This study suggests that while subcutaneous Botulinum Toxin Type A may offer short-term symptom improvement for female pattern hair loss, its effectiveness does not extend beyond three months.

In this study, intradermal injection of botulinum toxin was associated with increased hair growth in men with androgenetic alopecia through the suppression of TGF-β1 secretion from dermal papilla cells.

In this study of patients with androgenetic alopecia, botulinum toxin type A was found to significantly increase hair counts and improve hair density and coverage, with enhanced results observed when combined with oral finasteride, revealing a safe and effective treatment approach without adverse effects.

This review discusses the various therapeutic uses of Botulinum Toxin Type A and reports high levels of patient satisfaction with minimal adverse effects across several conditions, emphasizing its potential therapeutic importance.

Botulinum toxin is not effective for treating male hair loss.

In this retrospective analysis, patients with trichodynia who were unresponsive to standard treatments showed significant symptom improvement after receiving intradermal botulinum toxin type A, with nearly all patients benefiting, particularly those with scarring alopecia.

In this systematic review and meta‐analysis, botulinum toxin monotherapy was found to significantly increase hair density in patients with androgenetic alopecia, with optimal effects observed using a 100-unit dose every six months. These findings suggest potential efficacy but should be confirmed in larger, placebo-controlled trials.

This study found that both intralesional minoxidil 8% and botulinum toxin type A were equally effective in treating female pattern hair loss, with no significant difference in results between the two treatments.